Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 752 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oncologic Disorders Clear all
Completed Phase 1 Interventional

A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors

NCT01733004
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
MM-141
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
3
States / cities
Marietta, Georgia • Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 22, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

NCT00765921
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
ranibizumab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 22, 2026, 1:03 AM EDT
Enrolling by invitation Phase 3 Interventional

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

NCT05645536
View directory record Official record
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 51 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
17
States / cities
Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant (BMT)

NCT00833898
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer
Interventions
Paced respiration as part of PEPRR, PEPRR
Device · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 22, 2026, 1:03 AM EDT
Terminated Not applicable Interventional Results available

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00726830
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 22, 2026, 1:03 AM EDT
Suspended Phase 1Phase 2 Interventional

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

NCT04042116
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer
Interventions
Lucitanib, Nivolumab
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 22, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

NCT02756611
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 22, 2026, 1:03 AM EDT
Not listed No phase listed Observational

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

NCT03896958
View directory record Official record
Conditions
Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
Interventions
Not listed
Lead sponsor
SpeciCare
Industry
Eligibility
1 Month to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 22, 2026, 1:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community-Led Action Research in Oncology: Improving Symptom Management

NCT03208816
View directory record Official record
Conditions
Chemotherapy-induced Neutropenia, Chemotherapy-induced Nausea and Vomiting, Anxiety, Depression, Fatigue, Neoplasms
Interventions
symptom management program for chemotherapy patients
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 22, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity

NCT03598426
View directory record Official record
Conditions
Hypersensitivity Reactions
Interventions
Dexamethasone
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 22, 2026, 1:03 AM EDT
Terminated No phase listed Observational

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

NCT03391791
View directory record Official record
Conditions
Solid and Hematological Malignancies
Interventions
Genetically engineered T Cell Receptors
Genetic
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 22, 2026, 1:03 AM EDT
Completed No phase listed Observational

SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

NCT00898872
View directory record Official record
Conditions
Lymphoma
Interventions
cryopreservation
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2011
U.S. locations
82
States / cities
Anchorage, Alaska • Atlanta, Georgia • Austell, Georgia + 51 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Oct 22, 2026, 1:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

NCT02586857
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 22, 2026, 1:03 AM EDT
Active, not recruiting Phase 2 Interventional

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

NCT05907954
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
10
States / cities
Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 22, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue

NCT03198754
View directory record Official record
Conditions
Cancer-related Problem/Condition, Depression, Circadian Rhythm Disorders
Interventions
PEI Experimental Light, Comparison Light
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 22, 2026, 1:03 AM EDT
Completed Phase 2 Interventional

Biobehavioral Intervention in Gynecologic Oncology Patients

NCT02454036
View directory record Official record
Conditions
Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vulva
Interventions
BBI intervention
Behavioral
Lead sponsor
Rachel Miller
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 22, 2026, 1:03 AM EDT
Completed No phase listed Observational

Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWeR)

NCT03807492
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 22, 2026, 1:03 AM EDT
Recruiting Phase 2 Interventional

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

NCT05253495
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B, DOC Group C, MAD CPR 1 and 2, Pv-R CYVE 1 and 2, Pv-R CYVE-MTX 1 and 2, MAD CP, Pv-Cytarabine/etoposide, AD CP, Bv-AVD-R 1 and 2: COHORT IIa, Bv-NVD-R, Cycle 1-2, Bv-NVD-R, Cycle 1-4 SER, Bv-AVD-R, Bv-NVD-R, Cycle 1-4 RER, Bv-NAVD-R, Cycle 1-2, Involved Site Radiation Therapy
Drug · Radiation
Lead sponsor
New York Medical College
Other
Eligibility
3 Years to 39 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Gainsville, Florida • Vallhala, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 22, 2026, 1:03 AM EDT
Recruiting Not applicable Interventional

Advocacy, Partnership, Outreach, and Yielding Optimized Care for Oncology Patients

NCT07403981
View directory record Official record
Conditions
Colorectal Cancer
Interventions
CHW/P Navigator Support, Social Services Resource List
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 1:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

NCT02030067
View directory record Official record
Conditions
Solid Tumor, Metastatic Bladder Cancer
Interventions
RX-3117
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 22, 2026, 1:03 AM EDT
Completed No phase listed Observational

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

NCT04283539
View directory record Official record
Conditions
Cancer, Skin Disease, Immunotherapy, Patients With Solid Tumors Receiving Immunotherapy With an ICI Will be Randomized to Participate in an SDoH and Side Effects Navigation Program vs. Control
Interventions
systemic corticosteroid or biologic
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 99 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Denver, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 22, 2026, 1:03 AM EDT
Completed No phase listed Observational

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

NCT01110733
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
Not listed
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
68
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 22, 2026, 1:03 AM EDT
Completed Not applicable Interventional Results available

Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery

NCT02356471
View directory record Official record
Conditions
Malignant Gastrointestinal Neoplasm, Malignant Peritoneal Neoplasm
Interventions
Management of Therapy Complications Fitbit Zip (portable pedometer device), Questionnaire Administration, Quality-of-Life Assessment
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 22, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

NCT00216099
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pemetrexed, Folic Acid, Vitamin B12
Drug · Dietary Supplement
Lead sponsor
Christopher Sweeney, MBBS
Other
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
15
States / cities
Galesburg, Illinois • Elkhart, Indiana • Fort Wayne, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 22, 2026, 1:03 AM EDT